The H3N8 canine influenza virus represents a very rare event in adaptive evolution; the entire genome of the H3N8 equine influenza virus was transferred to dogs, and the virus adapted to the canine species to emerge as a new canine-specific virus. The first recognized outbreak of H3N8 canine influenza occurred in racing greyhounds in January 2004 at a track in Florida. Since then, the H3N8 canine influenza has been documented in 40 states and Washington, DC. The H3N8 strain of canine influenza virus is endemic in areas of Colorado, Florida, New York, and Pennsylvania. 
Clinical Signs
The majority of infected dogs exhibit the mild form of canine influenza. In the mild form, the most common clinical sign is a cough that persists for 10 to 21 days. Affected dogs may have either a soft, moist cough or a dry cough similar. Nasal and/or ocular discharge, sneezing, lethargy and anorexia may also be observed. Dogs may develop a purulent nasal discharge and fever (104-105 o F). The nasal discharge is usually caused by secondary bacterial infections, including Pasteurella multocida and mycoplasma species.
Some dogs are more severely affected with clinical signs of pneumonia, such as a high-grade fever (104°F to 106°F) and increased respiratory rate and effort. Thoracic radiography (chest x-rays) may reveal consolidation of lung lobes.
Epidemiology of Transmission
Almost all dogs are susceptible to the virus, and illness tends to spread among dogs housed in kennels and shelters. CIV can spread to other dogs by direct contact, through aerosolized respiratory secretions (coughing and sneezing) from infected dogs, and via contact with contaminated objects (fomites). Therefore, dog owners whose animals are coughing or showing other signs of respiratory disease should not expose their dog to other dogs. Clothing, equipment, surfaces, and hands should be cleaned and disinfected after exposure to dogs showing signs of respiratory disease.
Prevention, Treatment and Control
There is an approved vaccine to protect dogs against canine influenza A H3N8 available in the United States. It is unknown at this time whether this vaccine will protect against the H3N2 canine flu virus.
There are no specific therapeutic treatments for CIV. Often, antimicrobials are used to prevent or control secondary bacterial infections. For severely affected dogs, intensive care including antiinflammatory medication and fluid therapy may offer relief.
